1Knodell RG,Holtzman JL.Crankshaw DL.et al.Drug metabolism by rat and human hepatic microsomes in response to interaction with H2-receptor antagonists.Gastroenterology,1982,82 (1): 84～88 被引量：1
2Kampo News: Special Edtion on Liver Health, 2003. Honso USA,Inc. 被引量：1
3Tianhan Xue. Letter to the Editor. Science, 2003, 300:2 被引量：1
4Ama S F, Lok. Chronic hepatitis B. Hepatology, December, 2001 被引量：1
5Zoli M. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. CAancer, 1996, 78:977～985 被引量：1
6Hopf U. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitisCvirus (HCV). J Hepatol, 1990, 10:69～76 被引量：1
7Di Bisceglie AM. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology, 1991, 14:969～974 被引量：1
8Tremolada F. Long-term follow-up of non-A, non-B (type C) posttransfusion hepatitis. J Hepatol, 1992, 16:273～281 被引量：1
9McHutchiso JG. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results druingtherapy. J Viral Hepat, 2001, 8:414～420 被引量：1
10Poynard T. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT), Lancetl,1998, 352: 1426～ 1432 被引量：1
